Informace o publikaci

Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

Autoři

MÓCIKOVÁ Heidi PYTLIK Robert STEPANKOVA Pavla MICHALKA Jozef MARKOVA Jana KOREN Jan BURESOVA Lucie RAIDA Ludek KRÁL Zdeněk

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj Acta Haematologica
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1159/000381327
Obor Onkologie a hematologie
Klíčová slova Chemotherapy; Hodgkin's lymphoma; Nodular lymphocyte-predominant Hodgkin's lymphoma; Rituximab
Popis Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first-or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info